T uberculosis (TB) remains one of the leading single-agent infectious disease killers in the world, with approximately 1.7 million deaths from TB occurring in 2009 (21) . The continued human-to-human spread of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) is a worldwide threat, especially to developing countries such as China and India. In many areas where TB is prevalent and resources are limited, such as China's Guizhou Province, TB therapy is often empirical and the drug susceptibility profile of the Mycobacterium tuberculosis isolate is generally not determined before treatment. Therefore, timely determination of drug susceptibility profiles of M. tuberculosis clinical isolates would lead to more effective drug interventions and improve the quality of patient care.
Drug resistance surveys among TB patients in 10 provinces of China from 1996 to 2004 were reported recently (8) ; however, Guizhou Province was not included. Our recent survey results indicated that the Zunyi area of Guizhou Province had a high prevalence of MDR-TB among newly treated (8.1%) and previously treated (45.1%) TB cases (2) . Several spoligotyping studies of M. tuberculosis isolates from different provinces of China have also been reported recently (1, 12-16, 18, 20, 23) . Nevertheless, the genetic diversity and drug susceptibility profiles against seven anti-TB drugs for M. tuberculosis isolates from Zunyi were not determined previously, indicating the necessity of this study to assist in making informed TB treatment decisions and improve the treatment outcomes of patients with drug-resistant TB.
The Affiliated Hospital of Zunyi Medical College is one of the specialized centers in Guizhou Province that treat patients with MDR-TB and provides around 15,000 TB patients with outpatient treatment and inpatient critical care each year. In this study, we determined the genetic diversity and drug susceptibility profiles of 100 M. tuberculosis clinical isolates collected consecutively at this hospital between 2008 and 2009 (only one isolate per patient was collected and tested) and compared our results to those published studies with M. tuberculosis isolates collected from different areas of China.
Sputum specimens collected from TB patients were used to inoculate Lowenstein-Jensen slants. The TB diagnostic laboratory procedures recommended by the World Health Organization (22) were followed strictly for the preparation of media and inoculation and growth of mycobacteria in a biologic safety cabinet to avoid potential contamination of the cultures. The clinical isolates were determined to be M. tuberculosis before they were selected for this study. The collected TB culture samples were used for molecular typing and drug susceptibility testing (DST) against four firstline drugs (rifampin, isoniazid, streptomycin, and ethambutol) and three second-line drugs (capreomycin, levofloxacin, and ciprofloxacin). Among numerous epidemiologic methods for the molecular typing of M. tuberculosis isolates, spacer oligotyping (spoligotyping) is considered to be the simplest and best (3, 6) . Based on the variability of the direct repeat (DR) locus, spoligotyping can be performed to determine the genetic diversity and evolutionary relationships of M. tuberculosis isolates (5, 9). Therefore, we selected this method for molecular typing of collected M. tuberculosis isolates. Bacterial growth and genomic DNA isolation were carried out by the method of van Soolingen et al. (19) . Genomic DNA extracted from the standard M. tuberculosis strain H37Rv and Mycobacterium bovis BCG (obtained from the Chinese CDC) were used as controls. Methods used for detection and analysis of spoligotype patterns and database comparison were described previously (4) . For the drug susceptibility testing, the proportion method on Lowenstein-Jensen media was used to test isolates against seven antituberculosis drugs purchased from Sigma-Aldrich (St. Louis, MO) with M. tuberculosis strain H37Rv as the control. The drug concentrations used were as follows: 40 g/ml rifampin (catalog no. R3501), 0.2 g/ml isoniazid (13377), 4 g/ml streptomycin (S2522), 2 g/ml ethambutol (E4630), 40 g/ml capreomycin (C4142), 2 g/ml levofloxacin (28266), and 2 g/ml ciprofloxacin (17850).
The description binary and octal code for 100 isolates are listed in Table 1 , and 29 different spoligotype patterns were identified. In addition, 20 orphan spoligotypes (new patterns) were recognized from 23 isolates (Table 1 ) and added to the SITVIT database (Pasteur Institute of Guadeloupe) in the binary format. The remaining 77 M. tuberculosis isolates were clustered to nine superfamilies: 48 to the Beijing family, 13 to the T1 family, 5 to the T3 family, 4 to the T2 family, 3 to the MANU2 family, and one isolate to each of the Beijing-like, U, H3, and H3-T3 families ( Table 1) . Out of 100 isolates tested against four first-line drugs, 35 (35%) were drug susceptible, 65 (65%) were drug resistant, and of these 65, 30 were MDR-TB (Table 2) . Among 65 drug-resistant isolates, 49 (75.4%), 38 (58.5%), 36 (55.4%), 27 (41.5%), and 30 (46.2%) were resistant to streptomycin, isoniazid, rifampin, ethambutol, and isoniazid plus rifampin (MDR-TB), respectively. Among 45 isolates tested for the three second-line drugs, in addition to the four first-line drugs, 12 (26.7%), 11 (24.4%), and 7 (15.6%) were resistant to levofloxacin, ciprofloxacin, and capreomycin, respectively. Additionally, 4 out of 30 (13.3%) MDR isolates tested against three second-line drugs were XDR-TB, and three of them were not previously treated with anti-TB drugs.
To determine whether the Beijing genotype or new spoligotype patterns are correlated with more frequent drug resistance in the Zunyi area, we compared drug susceptibility profiles between isolates clustered to Beijing and non-Beijing families and with known and new spoligotype patterns (Table 2) . Results showed that isolates resistant to isoniazid, rifampin, MDR-TB, levofloxacin, ethambutol, and XDR-TB were found more frequently among the Beijing family than non-Beijing families, and isolates resistant to streptomycin, ciprofloxacin, and capreomycin were found less frequently among the Beijing family (47.9%, 17.6%, and 11.8%) than non-Beijing families (50.0%, 28.6%, and 17.9%) ( Table 2) .
Clinical M. tuberculosis isolates with new spoligotype patterns appeared to be correlated with more frequent drug resistance (78.3%) but not MDR (30.4%) compared to those with known spoligotype patterns (61.0% were drug resistant and 29.9% were MDR). Isolates resistant to isoniazid, levofloxacin, ciprofloxacin, and XDR-TB were found more frequently among those with known spoligotypes (39.0%, 30.8%, 30.8%, and 11.5%) than those with new spoligotype patterns (34.8%, 21.1%, 15.8%, and 5.3%) and isolates resistant to streptomycin, rifampin, ethambutol, and capreomycin were found less frequently among those with known spoligotype patterns than those with new spoligotype patterns ( Table 2) .
The Beijing family is the most prevalent lineage in China (4) Table 3) . Based on the results of Table 3 , the relationship between Beijing family isolates and drug resistance is still contradictory, with most of the studies showing no significant correlation. The observations that M. tuberculosis clinical isolates from the Zunyi area had higher genetic diversity and a lower percentage of Beijing family isolates, on top of the fact that the Zunyi area had a high prevalence of MDR-TB among new and previously treated TB cases (2) , support the notion that Beijing family isolates may not be linked to greater drug resistance. In summary, we analyzed the genetic diversity and drug susceptibility profiles of 100 M. tuberculosis clinical isolates and found that isolates collected in the Zunyi area were more diversified with more polymorphisms but clustered less frequently to the Beijing family compared to isolates from other provinces/cities of China, which supports the opinion that geographic location is one of the important factors determining the prevalence of Beijing family isolates. Drug susceptibility profiles against anti-TB drugs for M. tuberculosis clinical isolates collected at this hospital were used by physicians to choose appropriate regimens for different patients, which improved the treatment efficiency for patients with drug-resistant TB. In addition, 4 out of 30 MDR isolates (13.3%) tested for three of the second-line anti-TB drugs were XDR-TB, which is higher than two recent survey results from Beijing (6.3% [17] ) and Shanghai (6.28% [24] ). In conclusion, more systematic studies with clinical M. tuberculosis isolates collected from different geographic locations will be needed to confirm whether the Beijing family genotype and new spoligotype patterns are really correlated to more frequent drug resistance, especially multidrug resistance. 
